Search
Recombinant Cholera Toxin B Subunit
go.drugbank.com/drugs/DB11643ApprovedInvestigationalRecombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.
Categories: Compounds used in a research, industrial, or household settingAQ-13
go.drugbank.com/drugs/DB17749InvestigationalAQ-13 is an 4-aminoquinoline analog being investigated for the treatment of malaria.
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigationalParoxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalunmet medical need based on a surrogate endpoint. … [L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexLenograstim
go.drugbank.com/drugs/DB13144ApprovedWithdrawnLenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitOxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth … Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes.
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). … In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBarbexaclone
go.drugbank.com/drugs/DB09001ExperimentalSeveral reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties … Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital.
Mirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).
Anecortave acetate
go.drugbank.com/drugs/DB05288InvestigationalAnecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.